Moderna Interest Expense 2011-2025 | MRNA

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Moderna

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-87 M	-124 M	-45 M	-29 M	-6 M	-8 M	1.84 M	-1.88 M	-2.71 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.84 M	-124 M	-33.5 M

Quarterly Interest Expense Moderna

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	8 M	-4 M	-	-12 M	-27 M	-19 M	-	-51 M	14 M	-48 M	-	-7 M	-13 M	-13 M	-	-10 M	-2 M	-10 M	-	-3 M	-2 M	-1 M	-	-1.88 M	-1.88 M	-1.93 M	-	-1.03 M	171 K	-183 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
14 M	-51 M	-8.99 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	459 K	$ 4.75	-0.84 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	2.95 M	$ 3.02	-0.82 %	$ 233 M	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 208.81	-1.88 %	$ 5 B	Danmark
Aptevo Therapeutics APVO	472 K	$ 0.59	-36.2 %	$ 163 K	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.12	0.81 %	$ 7.51 B	Australia
BioVie BIVI	4.3 M	$ 1.23	-3.54 %	$ 1.82 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.22	24.06 %	$ 479 M	Israel
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 26.93	0.45 %	$ 1.3 B	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Axon Enterprise AXON	286 M	$ 584.75	-1.08 %	$ 44.3 B	USA
Aytu BioScience AYTU	-512 K	$ 2.49	-1.78 %	$ 15.6 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Catalyst Biosciences CBIO	1.04 M	$ 12.33	-0.32 %	$ 812 M	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Celldex Therapeutics CLDX	927 K	$ 26.29	-2.01 %	$ 1.69 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-7.26 M	$ 11.05	2.27 %	$ 715 M	USA
Biogen BIIB	250 M	$ 176.33	-	$ 25.7 B	USA
Cerevel Therapeutics Holdings CERE	10.6 M	-	-	$ 7.29 B	USA